
Index

A

- $\alpha 4\beta 2$ nAChRs, 166, 168
- $\alpha 7$ nAChR receptors, 168
- $\alpha 7$ nAChR subunit knockout mice, 159
- abstainers (nonsmokers)
 - characteristics of, 22
 - inclusion *versus* exclusion of, 222–223, 235, 323
 - nicotine patches, 377
- abstinence
 - in behavioral economics effects, 420
 - deficits, 350–351
 - effects of, 405, 408
 - event-related potential, 429
- abstinence-induced craving, 438
 - effects of, 405
 - measurements, 403
 - during smoking cessation, 441
- α -bungarotoxin binding, 165, 167
- ACE model, 249–250
- acetaldehyde (alcohol studies), 86–87
- acoustic startle reflex. *See* startle response
- active avoidance, 435
- acute stress mimicry of withdrawal symptoms, 448
- acute tolerance, 162–163
- ADA (Americans with Disabilities Act), 49
- Add Health (National Longitudinal Study of Adolescent Health), 197–198, 261, 517
- addiction. *See also* nicotine dependence;
substance use
 - clinical manifestations of, 79
 - as dependence, 77
 - DRD2* gene and, 32
 - versus* habituation, 24
 - models of, 293
 - versus* smoking, 24
 - stress and, 36
- additive components, 511
- adenosine knockout mice, 159
- adenosine systems, in nicotine reinforcement,
159–160
- ADH1*2* alleles (alcohol studies), 86–87
- ADHD. *See* attention deficit hyperactivity disorder
- adipose tissue, nicotine concentrations in, 145
- ad libitum (ad lib) self-administration, 415–416,
419
- administration, 145–149, 418. *See also* self-
administration
 - in drinking water, 148, 172
 - intravenous, 146, 156, 410
 - oral, 148, 154, 412
- adolescent(s)
 - alcohol use by, 516
 - cognitive control, 358, 380
 - delay discounting choices, 350
 - depression in, 351–352
 - event-related potential, 429
 - extraversion in, 349
 - first mood effects, 375–376
 - neuroticism in, 351, 352
 - nicotine deprivation learning deficits, 436
 - nicotine response in, 194–195
 - novelty seeking behavior, 27, 348
 - P300 amplitude in, 360
 - physiological changes in, 589
 - protective factors, 343
 - research limitations, 367
 - social influences on, 346–347, 517
 - substance-use vulnerability of, 195, 199, 200–
201, 212, 233–234, 261, 292–293
 - transition to adulthood, 195
 - use of genetic information by, 46–47
- adolescent developmental trajectories, 189–235,
592
 - age of smoking onset, 200–201
 - empirically identified, 202–214
 - example of, 223–233
 - future research directions, 233–234
 - psychopathology, 191–202, 292–293
 - statistical models, 214–223
 - substance use, 295–296 (*See also* substance-
use comorbidity; *specific substance*)
- adolescent nicotine dependence, 191–195
 - animal models of, 155, 194–195
 - biological vulnerability for, 100, 193–195,
200–201, 233
 - future research directions, 233
 - genetic studies of, 86, 264–266, 342
 - individual symptoms of, 192
 - measurement of, 192, 230–231, 264
 - time and exposure required for, 192–193
 - withdrawal symptoms, 192
- adolescent smoking, 371
 - antisocial behavior and, 200, 202, 211, 232
 - environmental influences on, 196–197
 - ethnic differences in, 213–214, 279

- gender differences in, 196, 199, 260, 263–264, 342
- gene-environment interactions in, 197–200, 259
- genetic research on, 195–200, 259–269
- heterogeneity in, 190, 233
- as indicator of adult nicotine dependence, 230–231
- latency between cigarettes, 371
- molecular genetic studies of, 198–199
- parental smoking and, 196–197, 200
- peer smoking and, 197
- prevalence of, 191
- twin studies of, 196, 259–262
- adolescent smoking initiation, 191
- age range in, 261–262
- heterogeneity of, 196, 201–202, 233
- progression to dependence, 341
 - genetic studies of, 263–264
 - rate of acceleration, 201–202
- psychosocial factors, 200, 202, 211
- risk profile, 211–212, 232
- shared environmental factors in, 260–261, 264, 280
- adoption studies, 196, 279
- ADRA1A* gene, 42
- adulthood, transition to, 195
- adult nicotine dependence, adolescent smoking indicators of, 230–231
- adult-onset events, 100
- adult smoking phenotype, limitations of, 190
- advertising
 - costs of, 21
 - in movies, 7, 20, 523
 - novelty seeking as response to, 348
 - protobacco, 7, 20, 30, 348
 - smoking index variable and, 30
- aerosols, nicotine, 147
- affective coping, 112–113
- affective response, 373–376
 - future research directions, 456
 - physiological measures of, 377–378, 445–446
 - regulation of, 358, 403, 443–449
- affiliation/empathy system, 362
- African Americans
 - adolescent smoking in, 213–214
 - genotypes linked to dependence, 47
 - linkage study focused on, 267
- age effects, 170–171
 - factor loadings by, 271–276
 - in smoking initiation assessment, 261–262, 279, 281, 322
 - in substance-use comorbidity, 322–323
- age-gene-environment interactions, 589
- age of onset, 26, 100, 371–372
 - developmental trajectories by, 200–201
- age-related macular degeneration, 46
- age-specific risk, measurement of, 35
- aggregate effects in complex pathways, 541
- aggression, 357
- agonists (activators), 143
- AHe mice, 435
- AIC (Akaike Information Criterion), 274, 312
- A inbred mice, 154, 165, 412, 422
- A/J mice, 435
- A/J×NMRI cross-bred mice, 154, 412
- Akaike Information Criterion (AIC), 274, 312
- alcohol use
 - adolescent, 516
 - in ATBC analysis, 496
 - Edwards's theory of, 82–83
 - Iowa gambling task as predictor, 350
 - nasal spray use correlated with, 373
 - in NHANES III analysis, 502
 - policies influencing, 294–295
 - as secondary reinforcement, 413
 - side effects, 86–87
 - tobacco use concurrent with, 98, 290, 296–298
 - empirical examples of, 307–323, 496, 502
 - health effects of, 290
 - modeling, 299–305
 - nicotine-dependence correlation, 369, 406, 411–412, 420
 - trajectories of, 295
- ALDH2*2* alleles (alcohol studies), 86–87
- alertness, 361–362
- allele(s)
 - identical by descent (IBD), 257, 258
 - variants of, 554
- allele frequency, 48, 258
- alpha subunits, 153
- Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), 487, 494–497
- alternative reinforcement, 417
- Americans with Disabilities Act (ADA), 49
- amphetamine, 412
- analysis of variance (ANOVA), 215
- analytic methods. *See also specific method*
 - developmental trajectories, 214–223
 - molecular genetic studies, 257–259
 - phenotypic research, 96–103, 113–118

anger, palliative effects on, 357
 animal studies. *See also* mouse models; rat models; *specific strain or study*
 ad lib administration in, 415
 adolescent nicotine exposure, 194–195, 589
 affective regulation, 443
 dependence, 134–135
 fetal nicotine exposure, 357
 impulsivity research in, 449–450
 reward studies, 372–373
 transfer to, 350
 ANOVA (analysis of variance), 215
 antagonists (inhibitors)
 CB1 receptors, 160
 for mu opioid receptors, 160
 muscarinic receptors, 141
 nicotine as, 143
 for nicotine dependence, 159
 anti-inflammatory effects of nicotine, 148–149
 antinociception, 162
 antisaccade task, 359
 antisocial behavior
 adolescent smoking and, 200, 202, 211, 232
 substance use and, 292–293, 304
 antitobacco stimuli, 20
 anxiety
 adolescent smoking and, 201
 nicotine linkage with, 352–353, 445
 anxiogenic effects of nicotine, 168
 apolipoprotein E testing, 48
 approach, *versus* impulsivity, 378–379
 approach-related risk, 339, 346–349, 362
 arousal, 378
ASN40ASP polymorphism, 407
 aspartame, 412
 association analysis, 258–259, 268–269, 280
 assortative mating, 251, 259, 280
 ATBC (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study), 487, 494–497
 ATR (Australian Twin Registry), 197, 260–261, 267
 attention, 361, 378, 432–434
 attentional bias, 440, 456
 attention deficit hyperactivity disorder (ADHD), 354–357
 adolescent smoking and, 201, 211
 as risk factor, 350, 433
 substance use and, 292–293, 304
 attrition biases, 224
 Australian Twin Registry (ATR), 197, 260–261, 267
 Automaticity subscale, 90–91

aversive mood symptoms, 443
 avoidance-related risk, 339, 351–354, 362

B

backcrossed mice, 151
 bacterial contamination, during administration, 145
 BALB/cBy mice, 164–165, 430–431, 435
 Barratt Impulsivity Scale, 450
 Bayes factors, 552, 570
 Bayesian analysis, 548–549, 570, 572
 Bayesian False Discovery Probability (BFDP), 573
 Bayesian Information Criterion (BIC), 310, 312
 Bayesian model averaging, 117
 Bayes model, 543
 BAY K 8644, 167
 behavior
 analysis of, 163–164
 antisocial
 adolescent smoking and, 200, 202, 211, 232
 substance use and, 292–293, 304
 drug-motivated, 404
 measurements of, 103
 nicotine and, 151–157
 phenotypes, 171
 response systems, 362
 smoking indices, 80
 substance-use comorbidity and, 322
 tolerance, 168
 traits, 344
 undercontrol, 98–99
 behavioral economics, 417, 420, 454
 behavioral genetics
 phenotypes in, 492
 of self-administration, 153–155
 in social context, 514–518
 behavioral modeling
 methodological issues with, 247–248
 of parental smoking, 246
 BFDP (Bayesian False Discovery Probability), 573
 BIC (Bayesian Information Criterion), 310, 312
 bioavailability of nicotine, 7, 20
 biochemical indices of smoking, 80, 415
 biochemical measures of self-administration, 97
 biochemical pathways, 561
 BioCyc, 561
 biological pathways, candidate, 105
 biological plausibility
 affective regulation, 443–445

- attention/vigilance, 432–433
- craving, 438–439
- event-related potential, 427–428, 429
- impulsivity, 449–450
- mood effects, 374
- reinforcement, 368–369, 410–414
- resting EEG activity, 425–426
- rewards, 372–373, 421–423
- startle response, 430–431
- working memory, 434–436
- biological vulnerability, in adolescent nicotine dependence, 194–195
- biomedical ontologies, 561
- biometric factor model, 253
- biometric modeling, 37–45, 86, 88–89, 514
- BioPAX Ontology, 561
- bitter taste, 84, 148
- BKW mice, 443
- blood pressure, 448–449
- $\beta 2$ nAChRs, 153
- $\beta 2$ nAChR subunit knockout mice, 159, 166
- Bonferroni correction, 546, 573
- brain
 - nicotine concentrations in, 145
 - stimulation, 373
 - upregulation in, 144
 - of young people, 589
- brain imaging, 360
- breakpoint
 - drug use, 418
 - nicotine use, 420
 - preferring to wait, 350
- breast milk, nicotine concentrations in, 145
- breeding
 - mice, 150–151, 411
 - rats, 411
- Brown University Transdisciplinary Tobacco Use Research Center (TTURC), 89, 521, 526
- BUB/Bn mice, 165, 412
- BUB inbred mice, 154
- buzz, 374

C

- calcium, 136, 139–140
- calcium calmodulin protein kinase II, 168
- calcium channel blockers, 162, 167, 168
- calcium signaling, 167–168
- Canadian National Longitudinal Survey of Children and Youth, 212

- cancer genetics, 50
- candidate biological pathways, 105
- candidate gene studies, 40–45
 - adolescent smoking, 342
 - discordant phenotype associations, 36
 - epigenetic differences, 37
 - linkage analysis, 32, 40–42, 267–268, 280–281, 589
 - multivariant data, 543–546
 - nicotine dependence, 42
 - prior knowledge of, 559
 - smoking association with, 24
 - SNP relationships over, 545
 - substance-use comorbidity, 325
 - trait pathways, 553
 - variants, 25, 35
- candidate neural systems, 343–346
- cannabis. *See* marijuana use
- Card Arranging Reward Responsivity Objective Test, 350–351
- CART (cocaine- and amphetamine-regulated transcript), 36
- cases, in association analysis, 258
- catechol-*O*-methyl transferase (*COMT*) gene, 269, 408–409, 430
- categorical covariates, 276–278
- causal contingent common (CCC) pathway model, 253, 263, 278–279
- causal differences between groups, 492
- causal paths
 - phenotypic research, 102, 107–110
 - sensitivity to, 105
 - smoking as, 352
 - types of, 111–113
- CBA mice, 435
- CB1 knockout mice, 160, 422
- C57BL/6 inbred mice
 - conditioned place preference in, 159, 422
 - dose-dependent effects, 165
 - fear conditioning in, 169, 432
 - five choice serial reaction time task in, 433
 - nicotine consumption, 155, 159
 - nicotine-dependence risk, 161
 - nicotine effects in, 435
 - novelty-seeking behavior in, 156
 - oral self-administration in, 412–413
 - prepulse inhibition in, 430–431
 - strain comparisons, 153–154, 164–165
 - in tolerance, 167
- C57BL/10 mice, 435

- C57BR/cd mice, 435
- CCC (causal contingent common) pathway model, 253, 263, 278–279
- CCK gene, 269
- CD-1 mice, 443
- CellDesigner, 561
- cell signaling, 161, 167–168
- Center for Antisocial Drug Dependence, 260
- Centers for Disease Control and Prevention, 498
- central nervous system (CNS), 344, 348, 353, 354
- centroid. *See* mean
- chain smoking, 37
- children
- effortful control in, 358
 - secondhand smoke from parental smoking, 246
 - self-control in, 344
 - sleep problems in, 357
 - smoking by, 371
- children of twins (COT) design, 251–252, 279, 511
- C3H inbred mice
- dose-dependence, 165
 - nicotine effects in, 431, 435
 - oral self-administration, 412
 - strain comparisons, 154, 164–165
 - tolerance in, 162
- chippers (light smokers)
- adolescent, 213, 232
 - delay discounting, 350
 - genetic factors and, 29
 - versus* heavy smokers, 43, 81, 83–84, 90, 94
 - prevalence of, 193
- choice procedure, 369–370, 416, 419–420
- cholecystokinin (CCK) gene, 269
- Christchurch, New Zealand (CNZ) study, 266
- CHRNA2 gene, 42, 376–377
- CHRNA3 gene, 376–377
- CHRNA4 gene, 268, 407–409, 412
- CHRNA5 gene, 342, 376–377
- CHRNA7 gene, 408, 409, 428
- CHRNA5-A3-B4 haplotypes, 100, 407
- CHRNA5-CHRNA3-CHRNA4 nicotinic receptor genes, 43
- CHRNA2 gene, 268, 407, 408, 409
- CHRNA3 gene, 342
- CHRNA3-CHRNA6 nicotinic receptor locus, 43
- chronic exposure, 405, 449
- chronic smoker endophenotypes, 403, 404–406
- affective regulation, 443–449
 - cognitive control, 432–438
 - craving, 438–443
 - electrophysiological measures, 425–432
 - future research directions, 452–457
 - impulse control, 449–452
 - investigation rationale, 406–410
 - motivational mechanisms, 410–424
 - summary/conclusions, 457–458
- chronic tolerance, 163
- CIDI (Composite International Diagnostic Interview), 81
- cigarette(s)
- availability of, 99
 - consumption of, 4, 20
 - design of, 7, 20
 - pricing of, 20, 21, 520
 - vendor locations, 521, 522
- Cigarette Dependence Scale, 79n
- Cigarette Evaluation Scale, 423
- cigarettes per day (CPD)
- in ATBC analysis, 496
 - with CYP2A6 gene variants, 418
 - delay discounting correlation, 452
 - as dependence measure, 79, 80
 - in factor analysis, 88–89
 - in NHANES III analysis, 502
 - nicotine metabolism and, 406
 - predictive value of, 80
 - recall reliability, 26–27
 - as smoking cessation predictor, 81, 413
 - in TUS-CPS analysis, 498, 499
- cigarettes per month, 91
- class extraction, model misspecification related to, 222
- classic dependence criteria, 84, 86
- classification bias, 493
- class I–IV phenotypes, 28–31
- class membership, for familial resemblance, 256–257
- clinical preventive services, 4
- Clinical Research Support System, 415
- cluster analysis
- developmental trajectories, 211, 217–223
 - discrete *versus* continuous phenomena in, 219
 - static *versus* dynamic, 219–220, 232
 - within-class variability in, 220–221, 233
- CNS (central nervous system), 344, 348, 353, 354
- CNZ (Christchurch, New Zealand) study, 266
- cocaine, 374, 456–457
- cocaine- and amphetamine-regulated transcript (CART), 36
- coexpression of receptors, 141, 142

- COGA (Collaborative Studies on Genetics of Alcoholism), 266
- cognition changes, 163–164
- cognitive control, 403, 424–425, 432–438
 - during adolescence, 380
 - alertness in, 361
 - electrophysiological measures, 425–432
 - as endophenotype measurements, 358, 360
 - impairment, 113
 - impulsivity and, 112, 378–379
 - physiological basis of, 381
- cognitive deficits reversal, 434–435
- cognitive measures, of craving, 440
- cohorts
 - effects of, 515
 - research models for, 519
- Collaborative Studies on Genetics of Alcoholism (COGA), 266
- colorectal polyps, 542
- commercial testing, 50
- common pathway model, 252, 270
- common-vulnerability model, 291–294, 306, 315–316
- communication of genetic findings, issues in, 45–50
- comorbidity
 - psychiatric (*See* psychiatric comorbidity)
 - substance-use (*See* substance-use comorbidity)
- complementary dimensions of dependence, 97
- complex traits
 - defining features, 31
 - genetic factors in, 35
 - genome-wide association studies for, 46
 - multiple determinations of, 22
 - replication difficulties, 45
 - sensitive genetic measures, 341
 - similarity of, 24–25
- Composite International Diagnostic Interview (CIDI), 81
- compulsive smoking, 80
- computational symbolic theory, 559–560
- COMT* gene, 269, 408–409, 430
- concurrent choice procedure, 416
- conditional independence, 256
- conditional triggers to smoke, 588
- conditioned place preference (CPP)
 - biological plausibility of, 372–374, 421
 - in mice, 157–158, 161, 422
 - in rats, 423
- conditioning, contextual, 163–164
- conduct disorder
 - adolescent smoking and, 201, 211, 232
 - definition of, 357
 - substance use and, 292–293, 304
- confounding factors, 32
- consensus, across indicators, 77
- constitutional hypothesis, 24
- construct
 - definition of, 75
 - emerging, 520
 - proximal, 522
 - refinement of, 25–27
- construct properties, 75
- construct validation, 33, 34, 35, 75–78
- consumption level
 - during adolescence, as indicator of adult dependence, 230–231
 - adolescent nicotine dependence and, 193
 - assessment of, 415, 418
- contamination, during administration, 145
- context-sensitive physiological measures, 363
- contextual conditioning, 163–164
- contingency table, smoking-drinking, 313, 315–316
- contingent factors, 247
- continuant, 541, 559
- continuous factors, 256
- continuous-level information, for behavioral modeling, 247
- continuous performance task (CPT), 362, 378, 433
- continuous phenomena, *versus* discrete phenomena, 219
- control, endophenotype measures of, 357–362
- control-related risk, 339, 354–357, 362
- controls, in association analysis, 258
- copy-number variation, 36
- core criteria, 76, 77
- core dependence dimension, 87–95
- core factors, 97, 168
- core strategy, 510
- cortisol, 447
- cosegregation of smoking behaviors, 24
- cost(s)
 - genetic testing, 50
 - smoking cessation, 593
 - tobacco use, 4, 21
- COT (children of twins) design, 251–252, 279, 511
- cotinine
 - biological activity of, 148
 - clearance factors, 39–40

as nicotine by-product, 406
 covariance, 32, 95–96, 341–342
 in latent growth curve models, 254–255
 in structural equation modeling, 248, 250
 CPD. *See* cigarettes per day
 CPP. *See* conditioned place preference
 CPT (continuous performance task), 362, 378, 433
 craving, 438–443
 abstinence-induced (*See* abstinence-induced craving)
 in adolescents, 192
 cue-induced (*See* cue-induced craving)
 dopaminergic systems associated with, 111
 effects of, 405
 measurement of, 403, 439–440
 Craving subscale, 90–91
 CREB activation, 160–161
 CREB mice, 422
 critical constituents, 25
 cross-cultural differences, 515–516
 cross-sectional studies, of substance-use comorbidity, 291
 cross-species analysis, 348
 cue(s)
 in animal studies, 411
 relapse, 99
 reward signaling, 350
 cue-induced craving, 438–439
 with dependence, 441–443
 effects of, 405
 future research directions, 456–457
 measurements, 403
 physiological basis of, 111, 588
 procedures to elicit, 440–441
 research limitations in, 456
 cue-self-administration response, 94
 cultural transmission
 adolescent smoking and, 198
 effects of, 515
 as environmental factor, 21
 phenotypic, 251
 research models for, 519
 twin studies of, 262
 cumulative effects, of pathogens, 103
 cumulative risk, measurement of, 35
CYP2A6 gene
 adolescent smoking and, 199
 analysis of, 554, 555
 association analysis of, 268

coding for, 408–409
 mood effects with, 376
 in nicotine metabolism, 22, 39–40, 149, 342, 406
 in smokers, 413
 variants in, 371, 418
Cyp2a5 gene variants, 149, 155, 413
CYP2B6 gene, 39
CYP2D6 gene, 39
 Cys-Cys pairs, 136
 cytochrome P-450 (CYP) system, 268

D

danger-alarm responses, 353, 354
 data-mining techniques, 541–542
 data sets
 ATBC analysis, 495
 NHANES III analysis, 500–501
 smoking cessation analysis, 493–494, 494
 TUS-CPS analysis, 498
 DAT/SLC6A3 (dopamine transporter protein), 268
 DBA/2 inbred mice
 conditioned place preference, 422
 dose-dependent effects, 165
 IV self-administration, 156
 nicotine consumption, 159
 nicotine effects, 435
 oral self-administration, 412
 prepulse inhibition in, 430–431
 strain comparisons, 153–154, 164–165
 tolerance in, 162, 163
 DDC (DOPA decarboxylase), 269
 definition variables, in structural equation modeling, 248
 dehydroepiandrosterone (DHEA), 447
 delay discounting
 definition of, 348
 in impulsivity, 349, 449, 450–452
 physiological basis of, 379
 study subjects for, 350
 deleterious effect prediction, 554
 dependence. *See also* nicotine dependence
 addiction as, 77
 core features of, 592
 definition of, 75
 distal measures of (*See* distal measures)
 maintenance of, 598
 model evaluation of, 78
 patterns, 94

- severity with comorbidity, 98
- study of, 24
- depression, 351–352
 - nicotine amelioration and, 443
 - smoking association with, 444
 - subthreshold, 352
- desensitization, 146
- developmental pathways, 100, 589
 - impact on trajectory study, 222
- developmental psychopathology, 191–202, 292–293
- developmental trajectories. *See* adolescent developmental trajectories
- DH β E, 159, 169
- DHEA (dehydroepiandrosterone), 447
- diabetes mellitus, 46
- Diagnostic and Statistical Manual of Mental Disorders (DSM)* criteria
 - adolescent smoking, 192, 264
 - attention deficit hyperactivity disorder, 356
 - dependence, 37–38, 40, 81, 86
 - poor agreement with FTND, 25–26
 - scales in, 79
 - substance-use disorder, 291
 - as syndromal medical model, 80–81
- diagnostic criteria, heritability of, 30, 38
- diagnostic inferences, 77
- Diagnostic Interview Schedule (DIS), 501
- diary prompts/responses, 527, 528–529, 530
- Digit Span test, 433
- diltiazem, 168
- direct drug infusion, 152–153
- direct-to-consumer marketing, 50
- DIS (Diagnostic Interview Schedule), 81, 501
- disadvantaged youth, 520
- discrete phenomena, *versus* continuous phenomena, 219
- discrimination, against nicotine dependence, 46–47, 49
- discriminative validity, 77
- discussion groups (OBO Foundry project), 560
- Disease Ontology (DO), 560
- disease risk, 541, 550
- disinhibition, common trait of, 292–293
- disorder markers, 107
- dispositional tolerance
 - acquisition of, 162
 - versus* behavioral tolerance, 164
 - in tolerance, 168
- distal influence, *versus* proximal influence, 519–522
- distal measures
 - agreement among, 88
 - early *versus* mature states, 74
 - genetic mapping, 78–81, 86–87, 103–105
 - versus* proximal measures, 516
- distress tolerance, 448
- distributional assumptions
 - in growth curve models, 255
 - in structural equation modeling, 249
- DNA methylation, 36
- DNA sequences analysis, 554
- DO (Disease Ontology), 560
- DOPA decarboxylase (DDC), 269
- dopamine
 - in attention deficit hyperactivity disorder, 356
 - attention-vigilance associations with, 434
 - impulsivity linkage with, 451–452
 - inactivation of, 430
 - mesotelecephalic, 171
 - midbrain circuits, 348, 349, 350
 - in nicotine binding role, 406–407
 - in nicotine dependence, 43, 410
 - receptors, 156, 343
 - regulation of, 540
 - reinforcement role of, 374, 407
 - reward pathways, 342, 349, 352
 - signaling, 160
- dopamine β -hydroxylase (D β H), 269
- dopamine hypothesis of dependence, 588
- dopaminergic neurons, in ventral tegmental area, 588
- dopaminergic systems
 - adolescent smoking and, 198–199, 201
 - association analysis of, 268–269
 - craving associated with, 111
- dopamine transporter protein (DAT/SLC6A3), 268
- dopamine transporter (*SLC6A3*) *9-repeat allele, 441
- dose of nicotine, 161, 165
 - differences in, 367, 416
 - distribution of, 370
 - standardization, 152
- dose-response curve, 162, 444
- double variant haplotype, 545
- downregulation, 144–145, 588
- downstream processes, 81–82, 106
- DRD4 (dopamine receptor), 268
- DRD5 (dopamine receptor), 268
- DRD4* exon III polymorphism, 199

- DRD2* gene, 409
addiction association with, 32
coding for, 408
commercial testing for, 50
dependence association with, 407
in craving, 441
variants, 198
- DRD4*7*-repeat allele, 376
- drinking. *See* alcohol use
- drinking-water administration, 147–148, 172
- drug addiction. *See* addiction; substance use; *specific drug*
- drug-motivated behavior, 404
- drug response comparison, 490–492, 491
- DSM. *See* *Diagnostic and Statistical Manual of Mental Disorders* criteria
- dual-trajectory model, of smoking-drinking trajectories, 315–316
- dynamic clustering
versus static clustering, 219–220, 232
within-class variability in, 220–221, 233
- E**
- early-emergent motive, 91
- early-onset smokers
risk for persistence, 200, 212–213, 230–231
substance use and, 292, 296–297, 315, 320
- early smoking experiences (ESE), 375
- early tobacco exposure, 101, 155
- ecological momentary assessment (EMA), 255, 525
- economic deprivation, 520
- educational attainment, adolescent smoking and, 227–228, 232
- Edwards's theory of alcohol dependence syndrome, 82–83
- EEA (equal environments assumption), 516–517
- EEG (electroencephalogram), 354, 403, 425–427
- effortful control, 358
- elasticity of demand, 417
- elation, 374
- electroencephalogram (EEG), 354, 403, 425–427
- electromyography (EMG), 431
- electrophysiological measures, 378, 425–432
- EMA (ecological momentary assessment), 255, 525
- EMG (electromyography), 431
- empirical-Bayes approach, 549, 551
- empirical search strategies, 117
- employment discrimination, 49
- employment status, of hard-core smokers, 35
- encoding prior knowledge, 571
- endogenous cannabinoid systems, 159, 160
- endogenous enkephalin system, 160
- endogenous event-related potentials (ERPs), 427
- endophenotypes, 5, 408–410
caveats, 110–111
characteristics of, 107–110
in chronic smokers (*See* chronic smoker endophenotypes)
conceptual issues, 381–383
criteria, 413
disorders associated with, 106
future research directions, 455–457, 594
gene linking in, 347, 409
measurement of, 349–351, 353–354, 355, 357–362
motivational effects, 452, 454–455
in network models, 558
nicotine dependence, 409, 453
phenotypes associated with, 5, 33–34
pre-exposure risk, 340–347
in psychiatric genetics research, 25
replicability of, 27
transitional, 107, 108, 200, 233
types of, 340
- enhanced clearance. *See* dispositional tolerance
- entities, 541, 559, 560
- environmental factors, 99–103. *See also* social context; *specific factor*
adolescent smoking, 196–197
comorbidity, 99
cue-induced craving, 438–439
enrichment, 36
in experimentation, 31
gender differences in, 38
gene expression variation from, 36–37
genetic factors in, 35, 515
importance of, 29
linkage analysis, 258
measurement of, 35
in nicotine dependence, 22, 23
nicotine use, 158
relative contribution of, 30
in smoking decline, 20
substance use, 294–295
twin studies, 251, 262, 279, 280
- environmental pathogens, 5, 25, 35

epidemiology, 31–37
 future research in, 594
 genetic, 257
 extended, 250–252, 262–269, 279, 280
 hierarchical modeling in, 570–571
 perspectives from, 514
 phenotypic definitions in, 493
 public health outcomes in, 492
 triangle, 513
epigenetics, 36
epistasis, 32–33
epistemology, 74, 77
equal environments assumption (EEA), 516–517
equifinality, 191, 220
ERPs (event-related potentials), 403, 427
ESE (early smoking experiences), 375
ethanol, 412. *See also* alcohol use
ethnic differences, in developmental trajectories,
 213–214, 279
etiologial architecture, 510–511, 515–518, 519,
 527, 530
etiology
 diverse, 82, 106
 matrix of, 509
 of phenotypic assay, 83
 of symptoms, 78
euphoria, 374
Event Ontology (EVO), 560
event-related potentials (ERPs), 403, 427
EVO (Event Ontology), 560
exchangeable classes, 551
excitatory tone, 141
executive function
 cognitive control and, 379
 definition of, 361
 nicotine dependence and, 34
Executive Order 13145, 49
exogenous event-related potentials (ERPs), 427
experimental design, basics of, 149–150
experimentation
 influences on, 31
 progression from, 30
exposure model, 365
extended structural equation modeling (XSEM),
 249
extended twin family studies, 250–252, 262, 279,
 280
extra-nicotinic mechanisms, 156–157
extraversion, 346, 348–349
extreme group membership, 96, 97

extreme groups
 alternatives to, 116–118
 constructing, 114–116
eyeblick response, 448

F

factor analysis, 37–38, 265
 consistency, 88
 correlation among, 80, 87
 DSM-IV correspondence with, 103
factor loadings, 271–278
factor mixture model (FMM), 256
factor models, 256
Fagerström Test for Nicotine Dependence (FTND),
 79–80
 as assessment tool, 405
 dependence criteria, 37–38
 FTQ as precursor to, 24
 linkage analysis, 40–42, 589
 poor agreement with *DSM*, 25–26
 reliability and validity of, 26, 79–80
 scales in, 79
 visuospatial attention association with, 434
Fagerström Tolerance Questionnaire (FTQ),
 79–80
 for adolescent smoking, 192, 230–231, 264
 as physical dependence measure, 79
 startle response inconsistency, 448
 in susceptibility loci mapping, 24
 test-retest reliability, 26
false discovery rates (FDRs), 542, 546, 570, 573
false positive reports, 570
familial resemblance, class membership for,
 256–257
family-based studies
 design of, 518
 ecological momentary assessment in, 526–527
 heritability documentation, 28–29
 new methodologies in, 521
family dysfunction scores, 33
family environment, adolescent smoking and,
 196–197
family history analysis, example of, 225, 230,
 232
fast-ionotropic nicotinic receptors, 136
FDRs (false discovery rates), 542, 546, 570, 573
fear conditioning, 169, 432, 435
fear responses, 353, 354
feeder stream influences, 81–82, 106

female smokers. *See also* gender differences
adolescent, 343
blood pressure changes in, 448
nicotine-dependence factors, 37, 38, 99
OPRM1 gene in, 419
statistics on, 21
twin studies, 515, 517
fetal nicotine exposure, 357
FHS (Framingham Heart Study), 266
final common pathway, 82, 93, 106
finite mixture model, 256
Finnish Twin Registry, 262
Finn Twin16-25 study, 307–323
methods, 307–310
results, 310–323
first experience with smoking. *See* initial
sensitivity
first-stage estimates, 572
Fisher, Ronald Aylmer, 22, 24
five choice serial reaction time task (5CSRTT),
432
five-class solution, example of, 226
fixed effects, 215–216
flunarizine, 168
FMM (factor mixture model), 256
focused interaction testing framework, 542
forced choice procedure, 416
formal model, 541, 559
Fosb knockout mice, 161
Foundational Model of Anatomy, 560
four-point Likert scale, 375
Framingham Heart Study (FHS), 266
F344 rats, 423
FTND. *See* Fagerström Test for Nicotine
Dependence
FTQ. *See* Fagerström Tolerance Questionnaire
future research. *See also specific topics*
crosscutting issues, 595–596
implications of, 588–591
understanding, 588–596

G

γ -aminobutyric acid (GABA), 157, 406–407
 γ -aminobutyric acid receptors, 43
GABA (γ -aminobutyric acid), 157, 406–407
GABAergic interneurons, 142
gateway theory of substance use, 292
GAW (Genetic Analysis Workshops), 266
gender differences. *See also* female smokers;
male smokers
adolescent smoking, 196, 199, 227–228, 260,
263–264, 342
animal studies, 155, 164
cross-cultural, 515
factor loadings by, 271–276
nasal spray use, 373
nicotine-dependence factors, 38, 99
nicotine-dependence heritability estimates,
279, 281
OPRM1 gene, 419
smoking initiation, 267
startle response, 378
substance-use comorbidity, 304
twin studies, 262, 517
gender heterogeneity, 273–274, 276–278
gene(s). *See also* candidate gene studies
endophenotype linkage risks, 347, 409
in nicotine dependence, 32, 43
gene-environment interaction, 33, 515
adolescent smoking, 197–200, 259, 346
biological process initiation, 591
environmental pathogens in, 25
in etiology, 509
investigation of, 546
substance-use comorbidity, 320
underuse of, 5
gene expression, 36–37
gene-gene interaction, 199, 343, 546
gene-nicotine dependence associations, 45–46
Gene Ontology, 560
gene-pathogen relations, 100–101
general growth mixture modeling (GGMM),
308–311
generational changes, in smoking, 515
Genes, Environment and Health Initiative, 531
genetically informative designs, 527
genetically modified mice, 444
Genetic Analysis Workshops (GAW), 266
genetic architecture, 510
genetic association studies, 554, 556–559
genetic drift, 150
genetic epidemiology, 257
extended, 250–252, 262–269, 279, 280
genetic factors
acute tolerance, 162–163
conditioned place preference, 159
craving, 441
detection of, 493

- in experimentation, 31
- importance of, 29
- measured, 4
- in nicotine effects, 22, 39–40, 539
- quantitative models, 512
- in reinforcement, 418
- relative contribution of, 30
- selecting for, 96–97
- genetic heterogeneity, 32
 - adolescent smoking initiation, 196, 201–202, 233
 - in developmental trajectories, 190, 233–234
 - gender, 273–274, 276–278
 - phenotypes, 341
 - population, 217
 - estimating, 218, 221–222
 - receptor, 139
- genetic heterogeneity models, difference in fit
 - between homogeneity models and, 274–275
- Genetic Information Nondiscrimination Act (GINA), 49
- genetic latent class models. *See* latent class analysis
- genetic latent growth curve models. *See* latent growth curve models
- genetic mapping, 73–75. *See also* phenotypic research
 - analytic strategies, 96–103
 - construct validation, 75–78
 - core dependence dimension, 87–95
 - covariation among measures, 95–96
 - distal measures of dependence, 78–81, 86–87, 103–105
 - multidimensional measures, 81–86
 - person factors implications in, 97–98
- genetic modeling, 245–281
 - methodological and conceptual issues, 247–248
 - statistical framework for, 248–259
- genetic polymorphism effects, 553–554
- genetic substrata, associated with tolerance, 162
- genetic testing, 46, 50
- genetic variants
 - biological processes associated with, 109
 - causal, 546
 - disease association with, 550
 - evaluation context for dependence, 76
 - phenotypes with, 102, 106, 109, 111
 - pleiotropic associations of, 47–50
 - selection of, 101
 - value of, 110
- gene-to-phenotype influence, 78
- gene-transcription cascades, 169
- genome(s)
 - candidate genes in, 24
 - data, 561
 - studies of, 589
- genome markers, linkage analysis, 257–258
- genome scan, 266–267
- genome-wide association studies (GWAS), 25, 44, 269
 - event-related potentials, 428, 430
 - FTND, 42–45
 - genetic variant findings, 589
 - genotyping technologies used in, 258–259
 - potential of, 45–46
 - results from, 342
 - susceptibility loci identification, 407–408
- genotyping
 - effects of variables on, 553
 - mouse strains, 150
 - P450, 39
 - with phase interaction, 545
 - phenotypes and, 560–562
 - technologies, 257–259
- geographic information systems (GIS), 520–521
- GGMM (general growth mixture modeling), 308–311
- GINA (Genetic Information Nondiscrimination Act), 49
- GIS (geographic information systems), 520–521
- global use, 4, 21
- GluR (glutamate receptor), 157, 169
- glutamate receptor (GluR), 157, 169
- GMM (growth mixture modeling), 202, 218, 221, 308
- go/no-go task, 358–359, 451
- government policies, 7, 20
 - effect on adolescent smoking, 193
 - substance use, 294–295
- grant funding, 45–46
- graph connectivity, 571
- grouping variables, for growth curve modeling, 216–217, 232–233
- group membership, stability of, across statistical models, 229–230
- growth curve, nonlinear, 255
- growth curve mixture modeling, 215–217, 248–249
- growth mixture modeling (GMM), 202, 218, 221, 308

growth process, random effects for, 220–221
gum. *See* nicotine gum
gustatory reaction to tobacco, 75, 84
GWAS. *See* genome-wide association studies

H

habituation, *versus* addiction, 24
half-life of nicotine, 147
haplotypes
 dependence and, 100
 disease association with, 544
 double variant, 545
hard-core smokers, characteristics of, 35–36
Hardy-Weinberg equilibrium, 545
head rush, 374
health care access, disparities in, 47
health effects of smoking, statistics on, 4, 21
heart rate, 351, 354, 440, 447
Heaviness of Smoking Index (HSI)
 components of, 37, 413
 predictive value of, 80, 89–90
 scales in, 79
 zero-order correlations in, 80
heavy smokers, 93
 delay discounting, 350
 diagnostic variance in, 89
 genetic factors in, 29
 versus light smokers, 43, 81, 83–84, 90, 94
 substance use and, 296–297, 315
Heavy Smoking Index, 265
hedonic impact of nicotine, 158, 372, 424
heritability
 adolescent nicotine dependence, 86, 342
 antisocial scores, 33
 anxiety, 445
 delay aversion, 351
 dependence, 37–38, 86, 433–434
 diagnostic criteria, 30, 38
 endophenotypes, 107
 estimates, 29–30
 event-related potential, 428, 429–430
 factors in, 28–29
 gender differences in, 279, 281
 impulsivity, 451
 neuroticism, 101
 nicotine metabolism/clearance, 38–40
 P450 genotype, 39
 prepulse inhibition startle response, 431–432
 response inhibition, 359
 resting EEG, 426
 smoking cessation, 406
 smoking heaviness, 90
 withdrawal symptoms, 30
 working memory, 437
heterogeneity. *See* genetic heterogeneity
hierarchical modeling
 estimation for, 575–576
 with ontologies, 551–552
 with prior knowledge, 570
 for statistical modeling, 117
 stochastic variable selection and, 547–549, 572, 573
 weighting in, 570
high-affinity nAChRs, 156, 159
higher-order joint actions, 546
high genetic proneness, 96
hippocampal activity, 141, 142
HISTONE proteins, 36
home smoking bans, 99
homogeneity models, 271
 difference in fit between heterogeneity models and, 274–275
homogeneous population
 assumption of, 248
 for growth curve modeling, 216–217
Hooked on Nicotine Checklist, 26
Horn-Russell Scale, 34
hostility, 357, 362, 377
Household Adult Questionnaire, 501
HSI. *See* Heaviness of Smoking Index
HTR5A gene, 42
5-HTT gene, 33, 269, 441
5-HTTLPR gene, 101, 199, 409
 in adolescent girls, 343
 in affective response, 112, 446
 coding for, 408
human clinical research
 affective regulation, 444–445
 electrophysiological measures, 426
 event-related potential, 428
 impulsivity, 450
 reinforcement, 413–414
HumanCyc database, 556
human genome, similarity with mice genome, 134
3-hydroxycotinine, 406
hyperactivity, 354, 356
hypertensive rats, 449

I

IBD (identical by descent), 257, 258
ICD-10 criteria, 80–81, 192
ICR mice, 159, 162, 163
ICSS (intracranial self-stimulation), 372–373, 421
identical by descent (IBD), 257, 258
illicit substances. *See* substance use; *specific drug*
impulse control, 449–452
impulsivity, 348
 in attention deficit hyperactivity disorder, 354, 356
 clinical research, 433, 450–451
 cognitive control and, 112, 378–379
 delay discounting with, 349, 350, 449, 450–452
 heritability, 451
 measurement of, 450–451
 neural incentive system association, 346
 preclinical research, 449–450
 in response inhibition, 359
incubation effect of initial exposure, 371
independent pathway model, 253
Indiana University Smoking Survey, 223–233
 data analysis, 225–226
 discussion, 231–233
 measures, 224–225
 procedures, 224
 results, 226–231
individual pathways to mature state, 105, 106
“infectious disease” model, 522
inflammation masking, 145
inhibitors. *See* antagonists
inhibitory interneurons, 141, 142
initial exposure response measures, 339
initial sensitivity, 27, 363–364
 future research directions, 380–381
 innate sensitivity, 364–368
 other responses, 373–380
 reinforcement, 368–372
 rewards, 372–373
innate sensitivity, 364–368
instrumental learning, 158
insurance companies, genetic testing and, 49
integrative model of nicotine dependence, 22, 23
integrative theory of triadic influence, 293
intercept, distribution of, 219, 306, 310
intercept models, initiation-based, 322
intermediate phenotypes, 341, 342. *See also* endophenotypes

International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) criteria, 80–81, 192
interpersonal dynamics, 517, 522–525
interval level, 247
intracranial self-stimulation (ICSS), 372–373, 421
intrathecal administration, 162
intrauterine events, 100
intravenous administration, 146
 humans, 415
 rodents, 152–157, 410–412
in utero nicotine exposure, 357
inveterate smokers, 87
ion-channel receptors, 143
Iowa gambling task, 350
IRT. *See* item response theory
item difficulty, 270
item response theory (IRT), 254
 empirical example of, 269–279
 versus sum score approach, 278

J

Jarvik, Murray, 24
journal publishing requirements, 45–46

K

kinship model, twin studies extended to, 250–252, 262, 279, 280
k-means clustering, 217
knockout mice, 159, 160, 161, 166, 422
Kraepelinian approach to diagnosis, 291
Kyoto Encyclopedia of Genes and Genomes, 561

L

laboratory-based measurements
 attention deficit hyperactivity disorder, 356
 consumption, 418
 endophenotypes, 349–351, 353–354, 357–362
late emergent symptoms, 90–91
latency to first puff, 415
latent class analysis, 80, 92, 98, 248–249, 256–257, 266, 280
latent class growth analysis (LCGA), 218, 226–229, 248–249
latent growth curve (LGC) models, 254–256, 266, 280

association data integrated into, 259
 substance-use comorbidity, 306, 308, 321
 latent phenotype model, 252, 270
 latent profile modeling, 90–91
 latent trait, 270
 latent variables, 77, 248, 256
 substance-use comorbidity, 306, 321, 324
 LCGA (latent class growth analysis), 218, 226–229,
 248–249
 LD (linkage disequilibrium), 543, 545–546
 learning associations, 349
 learning differences, 158, 169
 letter cancellation task, 433
 level, in latent growth curve models, 254
 Lewis rats, 411, 423
 LGC. *See* latent growth curve models
 liability models, of smoking behavior stages, 264,
 280
 lifetime regular smoking, definition of, 29
 ligand-activated ion channels, 143
 light smoking. *See* chippers
 likelihood-based approaches, in cluster analysis,
 217–218
 likelihood ratio tests, 310, 312–313
 linear growth, assumption of, 255
 linear model, 116
 linear regression, in structural equation modeling,
 248
 linear relations, 25
 linkage analysis, 257–258, 266–268
 candidate gene studies, 32, 40–42, 267–268,
 280–281, 589
 environmental factors, 258
 genome markers, 24, 257–258
 nicotine-dependence indices, 40–42
 linkage disequilibrium (LD), 543, 545–546
 Lister rats, 432–433, 444
 lithium-chloride conditioned place aversion, 161
 liver cytochrome P-450 enzyme CYP2A6. *See*
 CYP2A6 gene
 location of smoking, 527
 loci segregation, 40
 locomotor activity, 369, 422
 logarithm of odds (LOD) score, 40–42, 258, 267
 logistic regression curves, 91
 Long-Evans rats, 411
 longitudinal data
 growth curve modeling of, 218–219, 234
 on substance-use comorbidity, 291, 320
 Loss of Control subscale, 90–91

low genetic proneness, 96
LPAAT-delta gene, 42
 lung, nicotine concentration in, 145
 lung cancer, predisposition to, 44, 50

M

macrocontextual factors, 509, 514
 as moderators, 515–516
 macroenvironment proximal indicators, 521–522
 macular degeneration, age-related, 46
 magnetic resonance imaging (MRI), 351, 439,
 456–457
 maintenance of dependence, 589
 male smokers. *See also* gender differences
 adolescent, 342, 348
 blood pressure changes in, 449
 nicotine-dependence factors, 37, 38, 99
 OPRM1 gene in, 419
 statistics on, 21
 twin studies, 515, 517
 manifestations of dependence, 75
 Mannheim Study of Risk Children, 199
 MAO. *See* monoamine oxidase
MAP3K4 gene, 42
 marginalization
 of smoking, 4, 21
 of social groups, 47
 marginal nonnormality, 221
 marijuana use
 early pleasurable, 374
 tobacco use concurrently with, trajectories of,
 296–298
 modeling, 304–305
 trajectories of, 295–296
 marketing direct-to-consumer, 50
 Markov chain Monte Carlo (MCMC) methods, 542
 masking etiology, 82
 masking of causal factors, 74
 maternal care, 36
 mature subphenotypes, 82, 110–111
 maximum acute tolerance, 162, 165
 maximum price assessment, 418
 McGill University Study on the National History
 of Nicotine Dependence, 199
 MCMC (Markov chain Monte Carlo) methods, 542
 mean (centroid)
 cluster analysis, 217
 growth curve modeling, 255
 structural equation modeling, 248–249

- measured genetic factors, 4
- measurement invariance, 247, 255, 276, 280
- mecamylamine, 159
- mediation
 - of conditioned place preference, 161
 - by endophenotypes, 107–108
 - of nicotine, 160
- memantine, 156, 171
- memory, 379, 434–438
- Mendelian randomization, 118
- mesolimbic dopaminergic system, 410, 411
- metabolic tolerance, 97
- metabotropic glutamate receptor 5 (mGluR5), 156
- methodological issues
 - assessment precision, 520
 - behavioral modeling, 247–248
 - family-based studies, 521
 - future research directions, 383–384, 594
 - genetic modeling, 247–248
 - innate sensitivity research, 366–368
 - real-time interaction, 524–525
 - research limitations, 366–368, 376, 383–384
 - substance-use comorbidity, 321–323
- methyllycaconitine citrate (MLA), 159
- mGluR5 (metabotropic glutamate receptor 5), 156
- mice. *See* mouse models
- microchip analysis, 170, 258–259
- microcontextual factors, 509, 514
 - coding of real-time interaction, 524
 - as moderators, 516–518
- microsatellites, 543, 551
- microsocial context, quantifying, 522–525
- midbrain dopamine circuits, 348, 349
- Mid-South Tobacco Family (MSTF), 267
- migration levels, 516
- Minnesota Nicotine Withdrawal Scale, 446
- Minnesota Twin Family Study (MTFS), 196, 260, 360
- mirror tracing, 448
- misleading claims, 50
- misspecification, model, 222
- mixed models, developmental trajectories, 215
- MLA (methyllycaconitine citrate), 159
- model(s)
 - clarification of, 559
 - searching, 551
 - selection of, 547
 - with stochastic variable selection, 549–550, 551–552
- model fit, evaluation of, 310, 312–313
- modeling. *See also specific types of modeling*
 - phenotype (*See* phenotype modeling)
 - with prior knowledge, 570
 - selection algorithm, 577–578
 - uncertainties in, 546, 547, 549
- model misspecification, 222
- moderation of relationships, 248
- modified pairwise interaction, 545
- modulation
 - dopamine receptors, 156
 - nicotine rewards, 160
- molecular genetic studies, 266
 - of adolescent smoking, 198–199
 - analytic framework for, 257–259
- Monitoring the Future project, 299, 304
- monoamine oxidase (MAO)
 - in anxiety disorders, 353
 - neuroticism and, 351
 - in neurotransmitter breakdown, 540
- monoamine oxidase (*MAOA/MAOB*) gene, 269
- mood effects, 373–376, 380–381
 - in ATBC analysis, 497
 - measures of, 372
 - of nicotine, 366
- Mood Form of Diener and Emmons, 374–375, 446
- morning smoking. *See* time to first cigarette
- morphine, as nicotine substitute, 153
- Morris water maze, 435
- mortality statistics, 4, 21
- motivational mechanisms, 84, 403, 408
 - reinforcement, 410–420
 - rewards, 420–424
- Mouse Genome Informatics database, 150
- mouse models, 134–135, 418
 - adolescent exposure, 194–195
 - behavioral changes, 151–157
 - future research directions, 168–172
 - nicotine administration, 145–149
 - nicotine dependence, 149–151
 - nicotinic receptors, 135
 - customizing, 141–143
 - functional diversity of, 136–141
 - molecular biology of, 136
 - nicotine as agonist/antagonist, 143–144
 - upregulation, 144–145
- reward, 157–161
- startle inconsistency, 444
- strains, 134 (*See also* strain-specific differences; *specific strain*)
 - research options with, 592
 - selection of, 150–151

tolerance, 162–168
mouse-rat differences, 150
movies, smoking in, 7, 20, 523
MRI (magnetic resonance imaging), 351, 439, 456–457
MSTF (Mid-South Tobacco Family), 267
MTFS (Minnesota Twin Family Study), 196, 260, 360
multidimensional measures, of nicotine dependence, 81–86
multifinality, 191
multilevel analysis, difficulties of, 248
multiple trajectories, developmental, 191–202, 232–234
multivariate analysis
developmental trajectories, 215
latent growth curve models, 255
substance-use comorbidity, 315–316, 321
twin studies, 262–263
multivariate factor model, 252–253
multivariate normal distribution
in growth curve models, 255
in structural equation modeling, 249
multivariate normality, within-class, 221, 233
mu opioid knockout mice, 422
mu opioid receptors
in conditioned place preference, 160
in nicotine replacement therapy, 407
reward mediation, 419
in tolerance, 167, 168
muscarinic acetylcholinergic systems, 166, 168
muscarinic receptors
in aging, 170
blockading, 140–141
metabotropic, 136
muscle tension, 377–378
mutations
rate predictions, 554
for tolerance, 166
Muthén, Bengt, 218

N

nAChRs. *See* nicotinic acetylcholine receptors
Nagin, Daniel, 218
naloxone, 160
nasal spray. *See* nicotine nasal spray
National Cancer Institute, 498
National Center for Biomedical Ontology (NCBO), 561

National Comorbidity Study, 445
National Health and Nutrition Examination Survey (NHANES III), 487, 494, 500–503
National Institute of Mental Health Diagnostic Interview Schedule (DIS), 81, 501
National Institute on Drug Abuse Genetics Consortium, 43
National Institutes of Health, 531
National Longitudinal Study of Adolescent Health (Add Health), 197–198, 261, 517
National Survey on Drug Use and Health, 93
N-back task, 436
NCBO (National Center for Biomedical Ontology), 561
NDSS. *See* Nicotine Dependence Syndrome Scale
NEAD (Nonshared Environment in Adolescent Development) Project, 509, 524–525
Netherlands Twin Register, 262
Netherlands Twin Study of Anxious Depression (NETSAD), 266–267
network models, 554, 556–558
neural analysis, 349–351, 353–354, 357–362
neural incentive system, 346
neural networks modeling, 340–341
neural substrata, associated with tolerance, 162
neural systems, candidate, 343–346
neurexin 1 (*NRXN1*) gene, 43
neurobiological analysis, 348
neurobiological dependence pathways, 43
neurobiological systems, 344
neuroendocrine response, to stress, 354
neuroimaging, 360, 379–380
neuropeptide systems, 159, 160
neuroprotection, 170
neuroticism, 101, 351–353
neurotransmitter systems
in chronic tolerance, 166–167
in conditioned place preference, 159–161
New England Family Study, 526
NHANES III (National Health and Nutrition Examination Survey), 487, 494, 500–503
nicotine
administration of (*See* administration)
age-related response differences, 194–195
as agonist/antagonist, 143–144
anti-inflammatory effects of, 148–149
anxiogenic effects of, 168
behavioral changes from, 151–157
bioavailability of, 7, 20
enforcement timing, 369
in free-base form, 148

- frequency of use, 4, 21, 369–371, 413, 420
- hedonic impact of, 158, 372, 424
- neuronal activity induced by, 43
- physical changes from, 162
- pre-exposure risk (*See* pre-exposure risk)
- pretreatment, 420
- reinforcement (*See* reinforcement)
- rewards and (*See* reward)
- tolerance (*See* tolerance)
- nicotine aerosols, 147
- nicotine-binding sites, 135, 144
- nicotine choice, 369
- nicotine choice procedure, 416, 419–420
- nicotine cigarette choice paradigm, 419
- nicotine clearance
 - dispositional tolerance, 162, 164, 168
 - genetic factors in, 39–40, 539
- nicotine dependence, 20–22, 149–151
 - in adolescence (*See* adolescent nicotine dependence)
 - concurrent with substance use (*See* substance-use comorbidity)
 - construct refinement, 25–27
 - craving associated with (*See* craving)
 - crosscutting issues, 595–596
 - developmental pathways in, 589
 - distal measures of (*See* distal measures)
 - endophenotypes in, 409, 453
 - epidemiological concepts, 31–37
 - future research directions, 455–457
 - heritability of (*See* genetic factors; heritability)
 - historical perspective of, 22–25
 - inference of, 77
 - mouse models of (*See* mouse models)
 - phenotype (*See* phenotype(s))
 - progression research, 592
 - psychiatric disorders correlated with, 98
 - risk with, 375–376
 - smoking compared with, 87
 - versus* tobacco dependence, 75
 - treatment of (*See* smoking cessation)
 - understanding of, 588–596
- nicotine-dependence measures, 26, 28, 37–45, 73, 78, 79
 - adolescents, 192, 230–231, 264
 - example of, 225
 - invariance, 276, 280
- Nicotine Dependence Syndrome Scale (NDSS), 82–84
 - abbreviated, 500
 - as assessment tool, 405
 - subscales of, 90
 - in TUS-CPS analysis, 498
- nicotine deprivation memory deficits, 436
- nicotine gum
 - as consumption assessment, 415
 - effect on EEG activity, 426
 - in memory effects, 435
 - versus* placebo, 370
- nicotine metabolism
 - association analysis of, 268
 - catabolism of, 149
 - CPD variation and, 34
 - CYP2A6* gene in, 39–40, 149, 342, 406, 418
 - in dependence risk, 22, 342
 - in ontology example, 562–569
 - pathway, 556
- nicotine nasal spray
 - aversion with *DRD4**7-repeat allele, 376
 - as consumption assessment, 415
 - in current smokers, 374
 - memory effects of, 435–436
 - versus* placebo, 369–370
 - pleasurable responses to, 373
- nicotine patches
 - effect on EEG activity, 426
 - in memory effects, 435
 - on nonsmoking adults, 377
- Nicotine Pharmacokinetics Ontology (NPKO), 539, 561, 571
- nicotine replacement therapy (NRT), 406. *See also* smoking cessation
- nicotinic acetylcholine receptors (nAChRs), 134
 - association analysis, 268
 - as attention factor, 362
 - beta2-subunit (*CHRNA2*), 268
 - binding to, 588
 - blockading, 140–141, 143–144
 - chromosomal regions, 43, 44, 50
 - in chronic tolerance, 166–167
 - coding for, 408
 - customizing, 141–143
 - desensitization of, 146
 - fast-ionotropic, 136
 - functional diversity of, 136–141
 - high-affinity, 157
 - illustration, 409
 - as impulsivity mediator, 449
 - inactivation of, 143
 - inferences from, 152–153

initial sensitivity response with, 376–377
 molecular biology of, 136
 in nicotine binding role, 406–407
 in nicotine dependence, 411
 structure of, 136–138, 138
 tissue-specific responses, 71, 133
 in tolerance, 168
 upregulation of, 135, 144–145, 588
 nicotinic receptor subunits, 136–140
 CHRNA5/CHRNA3 genes, 342
 composition of, 139
 functional variants of, 140
 limiting expression, 141–143
 structure of, 136, 137
 nimodipine, 162, 167, 168
 nitric oxide, in conditioned place preference, 161
 7-nitroindazole, 161
N-methyl-D-aspartic acid (NMDA) glutamate
 receptors, 156
 NMRI outbred mice, 154, 412, 430
 nomological net, 76
 noncoding DNA sequences, 554
 nonlinear growth curves, 255
 nonnicotinic systems, 166
 nonnormality, 221
 Nonshared Environment in Adolescent
 Development (NEAD) Project, 509, 524–525
 nonsmokers (abstainers)
 characteristics of, 22
 inclusion *versus* exclusion of, 222–223, 235, 323
 nicotine patches, 377
 Northern California Twin Registry, 539, 540
 novelty seeking, 155–156, 199, 348–349
 by adolescents, 27
 nasal spray use in, 373
 neural incentive system association with, 346
 in substance use, 292–293, 348–349
 NPKO (Nicotine Pharmacokinetics Ontology), 539
 NRT (nicotine replacement therapy), 406. *See*
 also smoking cessation
NRXN1 gene, 43
NRXN3 gene, 43
 nutritional cancer prevention, 497

O

OBO (Open Biomedical Ontologies), 560
 OBO-Edit, 561
 OBO Foundry project, 560
 OBO Relation Ontology, 561
 observed variables, in structural equation
 modeling, 248
 occurrent, 541, 559
 oddball stimulus, 429
 olanzapine, 456
 ontologies, 539–541
 definition of, 541, 559
 development process, 560–562
 discussion of, 570–574
 methods, 541–543, 550–562
 nicotine metabolism, 562–569
 statistical approaches, 543–550
 Ontology Web Language (OWL), 561
 Open Biomedical Ontologies (OBO), 560
 Open Source software, 561
OPRM1 gene, 409
 coding for, 408
 gender differences in, 419
 in nicotine replacement therapy, 407
 in smokers, 423
 support interval proximity, 42
 oral administration, 147–149, 172, 412–413
 oral mucosa exposure to nicotine, 148
 ordinal data, analytical framework for, 247, 255
 osmotic minipump, 147
 outcomes of dependence, 75
 outliers, controlling for, 281
 OWL (Ontology Web Language), 561
 oxotremorine, 166–167

P

P3 amplitude, 294
 panic disorder, 353
 PANTHER Pathways databases, 556, 561
 parent(s)
 educational level of, 519
 twin studies extended to, 251, 262, 279, 280
 parental monitoring, as smoking counterforce, 22
 parental smoking
 adolescent smoking and, 196–197, 200, 262,
 346
 behavioral modeling of, 246
 nasal spray non-response, 377
 smoke-free home with, 523
 socialization effects from, 517
 parenting behavior, 342
 partition variation, 270, 280
 passive avoidance, 435
 patch. *See* nicotine patches

- path diagrams, in structural equation modeling, 248–250
- pathogen modeling, 100–101, 103
- PATO (Phenotype and Trait Ontology), 560, 571
- Pavlovian learning, 158
- PBT (problem behavior theory), 198, 292–294, 322
- PDAs (personal digital assistants), 525–527
- peers
 - as influence, 100, 346, 517
 - as smoking predictors, 523
- peer smoking, effect on adolescent smoking, 197
- penetrance, incomplete, 31
- peripheral nervous system (PNS), 344, 348
- P50 ERP, 427–428
- persistence
 - drug use, 417–418
 - negative affect with, 447
 - smoking (*See* smoking persistence)
- personal digital assistants (PDAs), 525–527
- personalized health care, 49–50
- person factors, 97–99
- PET (positron emission tomography), 439
- P300 event-related potential (ERP), 359–360, 429–430
- P450 genotype, 39
- pharmacokinetics, 37, 39, 118, 149, 542, 590
- pharmacokinetics ontology, 539, 561, 571
- phenotype(s)
 - assays, 83
 - association of, 33
 - behavioral, 171, 492
 - characteristics of, 109
 - components, 341
 - developmental progression of, 74
 - effects of variables on, 553
 - as endophenotypes, 5, 33–34
 - environmental, 34–36
 - framework, 27–31
 - genetic mapping, 96–103
 - genetic variants to, 102
 - genotyping and, 560–562
 - heterogeneity, 341
 - intermediate, 341, 342 (*See also* endophenotypes)
 - of mouse strains, 150
 - pathways, 23, 590
 - as points in smoking trajectory, 490
 - research pitfalls, 489
 - stages, 109
 - substance-use disorders, 316–318, 321, 324
- Phenotype and Trait Ontology (PATO), 560, 571
- phenotype modeling, 487, 488–492
 - examples, 493–503
 - methods, 492–494
 - summary, 503–505
- phenotypic assortative mating, 251
- phenotypic cultural transmission, 251
- phenotypic research, 105–106
 - analytic strategies, 113–118
 - causal paths, 107–110, 111–113
 - caveats, 110–111
 - summary, 118–119
- phenylthiocarbamide (PTC) haplotype, 84
- phosphatase and tensin homolog (*PTEN*) gene, 269
- physical aggression, 357
- physical responses to nicotine, 169
- symptoms, 26
 - in tolerance, 162–163, 164–165
- physiological measures of response reward, 351
- physiological startle. *See* startle response
- physiology
 - of affect, 377–378
 - of behavioral traits, 344, 345, 346
- Pittsburgh Youth Study, 214
- placebo, *versus* nicotine, 369–370, 420
- placenta, 145
- plasma nicotine levels
 - with IV injection, 146
 - tissue nicotine levels compared with, 145
 - in tolerance studies, 163–164
- pleiotropy, 32, 47–50
- PNS (peripheral nervous system), 344, 348
- point mutation, 444
- policy interventions, 34–35
- polymorphisms, 553–554. *See also* single nucleotide polymorphism
 - associations with, 116
 - different priors for, 571
 - in dopamine reward pathway, 342
 - emphasis within genes, 547
 - investigation of, 546–547
 - numerous, challenges of, 546–547
 - perturbations from, 554
 - trait variation effect of, 549
- PolyPhen (polymorphism phenotyping), 554
- polysubstance use, 43, 296
- population
 - frequency of genetic factors in, 86

- for growth curve modeling, 216–217, 234
- homogeneous, assumption of, 248
- in latent class analysis, 256
- response distribution in, 370, 373, 376–380
- in structural equation modeling, 248–249
- population heterogeneity, 217
 - estimating, 218, 221–222
- Positive and Negative Affect Schedule, 374–375, 446
- positron emission tomography (PET), 439
- postural hypotension, 449
- PPI (prepulse inhibition), 378, 403, 430–432
- preclinical research. *See also* animal studies; mouse models
 - affective regulation, 443–444
 - electrophysiological measures, 425–426
 - event-related potential, 427–428
 - impulsivity, 449–450
 - reinforcement, 410
 - rewards, 421–423
- precursors, class III phenotypes as, 30
- predictive validity
 - of genetic testing, 50
 - of primary motives scales, 90–91
- pre-exposure risk, 339, 340. *See also* smoking initiation and progression risk
 - endophenotypes, 340–347
 - future research directions, 381–385
 - initial sensitivity endophenotypes (*See* initial sensitivity)
- preproenkephalin knockout mice, 160, 422
- prepulse inhibition (PPI), 378, 403, 430–432
- price-demand curve, 417
- pricing, of tobacco products, 20, 21, 520
- primary motive scales, as predictors, 90–93
- prior covariate specification, 570–571
- prior knowledge, ontologies and, 553–562
- PR (progressive ratio) measures, 417–418, 420, 454
- probability discounting, 450–451
- problem behavior theory (PBT), 198, 292–294, 322
- problem use, 196, 198, 263, 294
- Profile of Mood States, 374–375, 446
- programmed lapse procedure, 454
- progression to smoking, 491
- progressive ratio (PR) measures, 417–418, 420, 454
- Project on Human Development in Chicago Neighborhoods, 520
- “proof of concept” analyses, 493, 494
- protective factors
 - in adolescents, 343
 - versus* vulnerabilities, 87, 114
- protein sequence data, 561
- protobacco advertising, 7, 20, 30, 348
- prototypes, of nicotine-dependence research, 27–28
- proximal indicators, 509
- proximal influence, 519–522
- proximal measures
 - versus* distal measures, 516
 - of social context, 518–527
- psychiatric comorbidity, 81, 98–99
 - with *DSM-IV* dependence, 26, 81
 - empirical examples of, 496, 502
 - resolving, 115
- psychiatric genetics research, 25, 27
- psychoactive alkaloid, 22
- psychological traits
 - approach-related risk, 346–349
 - avoidance-related risk, 351
 - control-related risk, 354–357
- psychometric common factor model, 252
- psychopathology
 - developmental, 191–202, 292–293
 - indices, 32
 - physiological basis of, 344
 - substance use and, 292–293, 304
- psychophysiological responses
 - to acute stressors, 448–449
 - craving, 440
- psychosocial factors
 - in adolescent nicotine dependence, 195
 - in adolescent smoking initiation, 200, 202, 211
- PTC (phenylthiocarbamide) haplotype, 84
- PTEN* gene, 269
- public health messages, 47
- public health outcomes, 492
- public settings, smoking in, 4, 20–21
- putative endophenotypes, 341

Q

- QSU (Questionnaire on Smoking Urges), 439
- QTL (quantitative trait locus), 258
- quantitative genetic models, 512, 522
- quantitative trait locus (QTL), 258
- quantity smoked measures, 28
- Questionnaire on Smoking Urges (QSU), 439

R

- racial background, 439. *See also* African Americans
- racism, associated with genetic information, 47
- random effects, 216
 - within-class, 220–221, 233
- rapid-decision context, 358
- Rapid Visual Information Processing (RVIP) task, 433
- rat models
 - adolescent nicotine exposure in, 194–195
 - alcohol/nicotine correlation, 369
 - conditioned place preference in, 423
 - self-administration of electrical stimulation, 421
 - sensitivity in, 364
 - strains, 411 (*See also specific strain*)
- Reactome, 561
- real-time contexts, 526
- real-time interaction, 524–525
- recall, 379
- receptor heterogeneity, 139
- recovery, from acute tolerance, 162
- regression models, 248, 542, 543, 550–551, 572
- regular smoking
 - definition of, 29
 - genetic factors in, 29–30
- reinforcement, 151–152, 155–156, 366–372, 380
 - alternative, 417
 - in cognitive control, 349
 - enhancing, 413
 - genetic influences in, 418
 - in initial sensitivity, 368–372
 - measurement of, 414–420
 - motivational mechanisms, 410–420
 - secondary, 411, 413
- relapse
 - environmental influences in, 95
 - physiological basis of, 588
 - predictors of, 77, 413, 434, 442, 444–445
 - time to first cigarette as predictor of, 80, 89
- relations between entities, 541, 559, 560
- relative measurements, 571
- reliability. *See also* test-retest reliability
 - of developmental trajectory research, 234
 - of nicotine-dependence measures, 26, 79–80
 - recall, 26–27
- reliability coefficients, 79
- religiosity, adolescent smoking and, 198
- repeated-measures data, developmental trajectories, 215, 222
- replication, of gene-nicotine dependence associations, 45–46
- research findings, communication of, issues in, 45–50
- research limitations
 - adolescent smoking, 367
 - adult smoking phenotype, 190
 - ATBC analysis, 497, 504
 - behavioral measures, 104
 - cue-induced craving, 456
 - data, 572
 - distal measures, 103
 - DSM, 103
 - extreme groups, 114–116
 - methodology, 366–368, 376, 383–384
 - NHANES III analysis, 503–505
 - nicotine-dependence measures, 103–104
 - Nicotine Dependence Syndrome Scale, 84
 - retrospective reporting, 367
 - self-report measures, 367
 - smoking cessation research, 454–455
 - statistics modeling, 570
 - tobacco dependence assessments, 95
 - TUS-CPS analysis, 500, 504
 - twin studies, 279–280
 - Wisconsin Inventory of Smoking Dependence Motives, 85–86
- residual familial factors (F), 258
- residual item variances, 270
- respiratory sinus arrhythmia (RSA), 361
- response inhibition, 358–359
- resting EEG activity, 425–427
- retail tobacco outlets, 520, 521
- retrospective reporting limitations, 367
- reward, 157–161
 - definition of, 349
 - for depressed smokers, 352
 - future research directions, 454–455
 - immediacy over magnitude, 348, 349
 - in initial sensitivity, 372–373
 - measurement of, 351, 366, 372–373, 380, 423–424
 - modulation of, 160
 - motivational mechanisms, 420–424
 - mu opioid receptor mediation, 419
 - preclinical studies, 157–161, 372–373, 421–423
 - signaling, 350
- reward and pleasure pathways, 22
- reward-discounting tasks, 350

- rimonabant, 160
- risk. *See also* pre-exposure risk; smoking
 initiation and progression risk
 age-specific, measurement of, 35
 approach-related, 339, 346–349, 362
 avoidance-related, 339, 351–354, 362
 control-related, 339, 354–357, 362
 cumulative, measurement of, 35
 disease, 541, 550
 with nicotine dependence, 375–376
 nicotine metabolism and, 22, 342
- risk factors
 adolescent smoking initiation, 211–212, 232, 350, 433
 substance use, 306, 340
- risk-taking behavior, by adolescents, 195, 199
- RNA analysis, 142
- rodent models. *See also* mouse models; rat models;
 specific strain
 adolescent nicotine exposure, 194–195
 adolescent sensitivity, 371
 intravenous self-administration, 410
 nicotine effects, 368, 435
 strain-specific differences, 418
- RSA (respiratory sinus arrhythmia), 361
- **RS578776* subunit gene, 43
- **RS16969968* subunit gene, 43
- Russell, M.A.H., 24
- RVIP (Rapid Visual Information Processing) task, 433
- S**
- saccharin, 148, 154, 159
- S allele, 112, 113
- sample size/followup
 in ATBC analysis, 497
 for developmental trajectory research, 234
 in TUS-CPS analysis, 498
- saturated model, 547
- SBML (Systems Biology Markup Language), 561
- schizophrenia, 428, 443
- secondary criteria of nicotine dependence, 76, 77
- secondary motives scales, 92–93
- secondary reinforcement, 411, 413
- secondhand smoke, 20, 246
- second-stage mixture model, 572
- self-administration
 ad libitum (ad lib), 415–416, 419
 genetic effects on, 146
 intravenous, 146, 152–157, 410–412
 oral, 412–413
- self-control, in children, 344
- self-insuring firms, 49
- self-report measures
 of affect, 446–447
 components of, 79
 of craving, 439–440
 ecological momentary assessment in, 525
 limitations of, 367
- SEM. *See* structural equation modeling
- semi-Bayes approach, 549
- semistructured paradigms, 524
- Sensation Seeking Scale, 377
- sensitivity
 of measurements, 341
 modeling, 363–364, 364
 periodic, 96
- sensitivity analysis, 570
- sensory measures, 403
- Sensory Questionnaire, 423
- sequential process model, of substance-use
 comorbidity, 304
- serotonin
 association analysis, 268–269
 genetic variation in, 343
 metabolism of, monoamine oxidase in, 353
 regulation of, 540
 smoking cessation and, 407
- SES. *See* socioeconomic status
- seven-point Likert scale, 372
- shared environment effects
 in adolescent smoking, 197, 260–261, 264, 280
 twin studies, 251, 280
- Shiffman-Jarvik Withdrawal Scale, 440
- Shiffman Nicotine Dependence Syndrome Scale.
 See Nicotine Dependence Syndrome Scale
- sibling(s)
 IBD configurations for, 257–258
 smoking epochs of, 531
 as smoking predictors, 523
 socialization studies, 517
 twin studies extended to, 251, 262, 279, 280
- Sibling Partners Study, 526
- sickle cell discrimination, 47
- side effects
 from drinking-water administration, 172
 from intravenous administration, 146
- SIFT (Sorting Intolerant From Tolerant)
 procedure, 554

- simultaneous effect of genes, 32–33
- single-factor dependence, 79n
- single-factor structure, 81
- single-group growth curve model, 219
- single nucleotide polymorphism (SNP)
 - candidate gene variants, 25
 - disease association with, 544
 - genotyping, 43, 257–259
 - nonsynonymous coding, 554
 - as reflection of underlying effects, 546
 - relationships over candidate genes, 545
 - relevance of, 570
 - in whole-genome research, 4
- situational dependence, 27
- six-class solution, example of, 227–228
- skin conductance, 354, 377–378
- skin temperature, 440
- SLC6A3* gene, 198
- SLC6A4* gene, 32, 101, 112, 113
- sleep problems, in children, 357
- slope
 - distribution of, 219
 - factor loading and, 275–276
 - in latent growth curve models, 254, 306, 310
- 129S6 mice, 430
- SMOFAM (Smoking in Families Study), 267
- smoke-free laws, 520
- smoke-free settings, 20, 30, 523
- smokeless tobacco, 147
- smokers, characteristics of, 22
- smoking
 - bans on, 99
 - decline in, 20
 - developmental phenotypes (*See* adolescent developmental trajectories)
 - first experience with (*See* initial sensitivity)
 - frequency of, 369–371, 413, 420
 - during illness, 79, 80
 - nicotine dependence compared with, 87
 - quantitative genetic model and, 512
 - status, 28
 - transition levels, 42–43, 488–490
- smoking cessation
 - age-related changes in, 170
 - barriers to, 4–5, 46
 - CHRNA2* gene in, 407
 - commercial testing, 50
 - comparison groups changes, 493
 - data sets in, 493–494, 494
 - definition of, 492
 - delay discounting factor in, 350
 - demand for, 21
 - difficulties of, 97
 - drugs for, 160
 - failures in, 44–45
 - FTND predictions of, 80
 - future research directions, 454
 - gender differences in, 38
 - heritability in, 406
 - monoamine oxidase decrease during, 351
 - research limitations in, 454–455
 - serotonin pathway and, 407
 - subthreshold pretreatments, 162
 - success predictors, 81, 89, 413, 434
 - symptoms of, 447
 - tailored, 48
- smoking index variable, 30
- Smoking in Families Study (SMOFAM), 267
- smoking initiation, 31, 42
 - adolescent (*See* adolescent smoking initiation)
 - assessment of, age effects in, 279, 322
 - definition of, 29
 - gender differences in, 267
 - linkage analysis of, 267
 - versus* persistence, 406
- smoking initiation and progression risk, 346, 491.
 - See also* pre-exposure risk
 - approach-related, 346–349
 - avoidance-related, 351–353
 - control-related, 354–357
 - endophenotypic measures, 349–351, 353–354, 357–362
 - future research directions, 362–363
- smoking level
 - measurement of, example of, 224–225
 - substance-use comorbidity and, 308, 322
- smoking pattern, factor analysis of, 265
- smoking persistence, 29, 30, 406
 - definition of, 29
 - early-onset smokers' risk for, 200, 212–213, 230–231
- smoking topography devices, 415, 418
- SNP. *See* single nucleotide polymorphism
- social context, 509, 510–511
 - adolescent smoking, 193, 198
 - behavioral genetics in, 514–518
 - future research directions, 527–532
 - proximal measures of, 518–527
 - rationale for, 511–514
 - substance use, 294–295

- social development model, 293
- socioeconomic status (SES)
 - adolescent smoking and, 232
 - distal to proximal influence, 519–522
 - of hard-core smokers, 35
 - nuanced approaches to, 519–520
- socioregional influences, 515–516
- “softening” of smoking, 193
- software
 - association analysis, 259
 - item response theory, 270
 - linkage analysis, 258
 - ontology, 561, 562
- Sorting Intolerant From Tolerant (SIFT)
 - procedure, 554
- SourceForge Web site, 562
- species-specific responses, 134
- specific-factor models, of substance use, 306–307, 315–316
- speed congenics, 151
- spinal cord minipumps, 163
- spouses, socialization effects from, 517
- Sprague-Dawley rats, 411, 431, 432–433
- stage models, developmental trajectories, 233
- startle-probe measures, 113
- startle response
 - as affective response, 447–448
 - in humans, 377
 - increases in, 444
 - prepulse inhibition of, 378, 403, 430–432
 - test-retest reliability of, 446–447
- state laws, against genetic discrimination, 49
- static clustering, *versus* dynamic clustering, 219–220, 232
- statistics
 - approaches to, 543–550
 - combining genetic studies with, 248
 - developmental phenotypes, 214–231
 - modeling, 248–259, 570
 - ontological knowledge in, 572
- ST/b inbred mice, 154, 155, 412–413
- stem cells, 151
- Sternberg Memory Task, 379, 436–437
- stigma, nicotine dependence as, 46–47
- stochastic variable selection
 - hierarchical modeling and, 547–548, 572, 573
 - model selection with, 549–550, 551–552
- stop-go task, 359
- strain-specific differences
 - aging, 170
 - conditioned place preference, 158
 - DNA markers, 151
 - five choice serial reaction time task, 432–433
 - genetic, 150
 - mouse models, 153–154, 164–165, 412–413
 - nicotine effects of, 135, 161, 169, 418
 - nicotinic acetylcholine receptors, 172
 - rat models, 411
 - tolerance, 164
 - unraveling of, 142
- strain surveys, 422
- stress, 351
 - as influence, 100
 - influences on, 36
 - neuroendocrine response to, 354
 - response mediators, 143
- Stroop interference task, 379, 440, 451, 452
- Stroop paradigm, 113
- structural equation modeling (SEM), 248–249
 - combined with latent class models, 256
 - of developmental trajectories, 215
 - linkage analysis and, 257–258
 - for twin data, 249–257
- study participants, selection of, 490–492
- subcutaneous administration, 147, 172
- subpopulation
 - in latent class analysis, 256
 - in structural equation modeling, 248–249
- subPSEC (substitution position-specific evolutionary conservation), 554
- substance use. *See also specific substance*
 - adolescent, shared environmental influences in, 261
 - age-dependent vulnerability to, 195, 198, 200–201, 212, 233–234, 292–293
 - attention deficit hyperactivity disorder in, 356
 - common-vulnerability model, 291–294, 306, 315–316
 - dopamine in, 410, 588
 - early pleasurable use, 374
 - environmental factors influencing, 294–295
 - interpersonal dynamics in, 522
 - Iowa gambling task as predictor, 350
 - modeling of, 43
 - nasal spray non-response, 377
 - novelty seeking in, 292–293, 348–349
 - prevention of, research approaches, 294–295
 - risk factors for, 340
 - specific-factor models, 306–307, 315–316

substance-use comorbidity, 289–325
 association between smoking trajectories and, 296–298
 empirical examples of, 307–323, 496, 502
 future research directions, 323–324
 gender differences in, 304
 gene-environment interactions in, 320
 importance of studying, 290–292
 informative phenotypes for, 316–318, 321, 324
 literature review, 295–296
 mechanisms underlying, 291–292
 methodological issues, 321–323
 modeling, 298–307
 risk factors, 306
 two-stage models of, 323
substance-use disorders
 common *versus* specific liability to, 292–295
 diagnosis of, 291
 shared genetic risk for, 294
substitution position-specific evolutionary conservation (subPSEC), 554
subthreshold depression, 352
sucrose, 154–155, 412
support interval, 40, 42
Surgeon General's Report (1964), 24
Surgeon General's Report (1979), 24
susceptibility loci mapping, 24. *See also* candidate gene studies
sweat gland activity, 440
Swedish Twin Registry, 515
Swiss mice, 435
Swiss-Webster mice, 158, 161
switching, between trajectory groups, 255–256
systems biology, genetic association studies and, 554, 556–559
Systems Biology Markup Language (SBML), 561

T

targeted treatment, 21–22
task performance, with nicotine deprivation, 436
Taste/Sensory Processes subscale, 84
taxon, nicotine dependence as, 93–94
team sports, as protective factor, 343
temperament-based model, 343–344
test performance, definition of, 75
test-retest reliability
 acoustic startle reflex, 446–447
 ad lib smoking, 415

 diagnostic tools, 81
 event-related potential, 429
 mood effects tests, 375
 nicotine-dependence measures, 26–27, 29
 prepulse inhibition startle response, 431
thapsigargin, 167
theta rhythm (slow-wave activity), 362
TH (tyrosine hydroxylase) gene, 198–199, 269
threshold
 factor loading and, 275–276
 as “smoker,” 42
time to first cigarette (TTFC)
 during adolescence, as indicator of adult nicotine dependence, 230–231
 correlations with, 90
 factor analysis of, 88–89
 nicotine metabolism association, 34
 as physical dependence measure, 79
 as quitting predictor, 80
time to maximum tolerance, 162
tissue levels of nicotine, *versus* plasma levels, 145
Tobacco Craving Questionnaire, 440
tobacco dependence, *versus* nicotine dependence, 75
tobacco industry, 24
tobacco policies, 7, 20
 effect on adolescent smoking, 193
 substance use policies and, 294–295
tobacco settlement dollars, 4
tobacco use. *See also* nicotine
 frequency of, 4, 21, 369–371, 413, 420
 history of, 27–28
 smoke compounds, 588
Tobacco Use Supplement, U.S. Census Bureau' Current Population Survey (TUS-CPS), 487, 494, 498–500
tolerance, 162–168
 genetic effects on, 146
 to repeated doses, 158
Tolerance subscale, 90–91
TPH gene, 269
trace fear conditioning, 435
transcription factor CREB, 160–161, 422
transcription factor Fosb, 161
transcription levels, alterations in, 40
transdisciplinary framework, 521
Transdisciplinary Tobacco Use Research Center (TTURC), 89, 521, 526
transitional endophenotypes, 107, 108, 200, 233
translational validation, 172

TRPC7 gene, 43
 129T2/SvEmsJ mice, 431
 TTFC. *See* time to first cigarette
 TTURC (Transdisciplinary Tobacco Use Research Center), 89, 521, 526
 TUS-CPS (Tobacco Use Supplement, U.S. Census Bureau's Current Population Survey), 487, 494, 498–500
 twin studies. *See also specific study*
 adolescent smoking, 196, 259–262
 affective regulation, 446–447
 cross-substance concordance, 317, 319–320
 CYP2A6 effect, 40
 delay aversion, 351
 ecological momentary assessment, 527
 epigenetic regulation, 36
 equal environments assumption in, 516–517
 event-related potential, 428, 429
 extended family, 250–252, 262, 279, 280
 factor analysis, 88–89
 factor mixture models, 256
 genomic studies, 589
 heritability of dependence, 28–29, 86, 342, 406
 impulsivity, 451
 limitations of, 279–280
 multivariate, 252–253, 262–263
 P300 amplitude, 360
 prepulse inhibition startle response, 431
 resting EEG, 426
 smoking habits, 22, 24
 smoking initiation, 31
 structural equation modeling, 249–257
 substance-use comorbidity, 307–323, 324
 tobacco use history, 38–39
 working memory, 437
 two-factor structure, 81
 two-stage genetic models, initiation *versus* progression, 323
 tyrosine hydroxylase (*TH*) gene, 198–199, 269

U

univariate analysis, substance-use comorbidity, 322
 unmeasured genetic factors, 4, 511
 upregulation, of nicotinic receptors, 135, 144–145, 588
 U.S. Task Force on Community Preventive Services, 4

V

validity
 of developmental trajectory research, 234
 discriminative, 77
 predictive, 50, 90–91
 variables
 independent, 495–496, 498–499
 observable, 77
 ontologies to represent knowledge about, 558–559
 perturbations from, 554
 in structural equation modeling, 248
 variance
 in latent growth curve models, 254
 partitioning, 270, 280
 ventral tegmental area (VTA), 152–153, 588
 verapamil, 167, 168
 VET (Vietnam Era Twin) Registry, 263–264
 videotaped paradigms, 524
 Vietnam Era Twin (VET) Registry, 263–264
 vigilance, 432–434
 Virginia 30,000 Study, 262
 Virginia Twin Registry, 264, 269–279
 measures, 269–270
 methods, 270
 results, 270–276
 study conclusions, 276–279
 subjects, 269
 Virginia Twin Study of Adolescent Behavioral Development, 260
 visuospatial attention, 434
 VLMR LR (Vuong-Lo-Mendell-Rubin likelihood ratio) test, 310, 312
 VTA (ventral tegmental area), 152–153, 588
 vulnerability
 of adolescents, 343
 differences in, 22
 modeling, 363–364
 protective factors, 87, 114
 Vuong-Lo-Mendell-Rubin likelihood ratio (VLMR LR) test, 310, 312

W

Wald test, 544
 watershed model, 78–79, 81–82
 WCST (Wisconsin Card Sorting Test), 378, 436
 Wechsler Adult Intelligence Test-Revised, 433
 whole-environment scan, 530

whole-genome association studies, 4
whole-genome linkage scans, 589
whole-genome quantitative transcript screening, 170
wild-type mice
 conditioned place preference in, 159, 160, 161, 422
 in CREB activation studies, 160
 in nicotine reinforcement, 159
WinBUGS, 549
Wisconsin Card Sorting Test (WCST), 378, 436
Wisconsin Inventory of Smoking Dependence Motives (WISDM), 84–86, 85
 as assessment tool, 405
 subscales of, 90–93
Wistar rats, 425, 431, 449
withdrawal symptoms
 in adolescents, 192, 194
 cellular changes, 147
 environmental influences in, 95
 heritability of, 30

 negative affect, 443
 physical dependence inference from, 77
 physiology of, 588
 severity of, 97, 413, 447
 support interval for, 40
within-class variability, estimation of, 220–221, 233
working memory, 434–438
World Health Organization, 80–81
World Mental Health Survey Initiative, 81

X

XSEM (extended structural equation modeling), 249

Z

zygosity, function of, in substance-use phenotypes, 316–317, 320

